

Special Issue

Poor Ovarian Response: From Bench to Bedside

Message from the Guest Editor

Advances observed in the field of reproductive medicine over the last four decades have led to the development of highly efficient ovarian stimulation protocols, subsequently improving reproductive outcomes.

However, there is a special category of women who fail to adequately respond to controlled ovarian stimulation, also known as “poor responders”. Numerous underlying mechanisms have been proposed to be implicated in POR pathogenesis, from follicular insensitivity to exogenous gonadotrophins, down to even lifestyle parameters. Additionally, several associations and causative relationships regarding POR have been proposed, ranging from advanced maternal age and reduced ovarian reserve to genetic or even iatrogenic factors. Despite the fact that POR has been investigated for almost three decades, there is no consensus yet with regard to POR patient categorization and characterization, subsequently leading to discrepancies regarding POR management among clinicians worldwide.

Considering the significance of improving POR patient performance, we invite researchers to contribute original research articles and reviews to this Special Issue.

Guest Editor

Dr. Theodoros Kalampokas

Second Department of Obstetrics and Gynecology, Aretaieion University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece

Deadline for manuscript submissions

closed (31 December 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/176979

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).